Abemaciclib plus endocrine therapy (ET) for HR+, HER2-, node-positive, high-risk EBC: results from a pre-planned monarchE overall survival (OS) interim analysis (IA), including 4-year efficacy outcomes

Basit Öğe Kaydı
dc.contributor.authorJohnston, S.
dc.contributor.authorToi, M.
dc.contributor.authorO'Shaughnessy, J.
dc.contributor.authorRastogi, P.
dc.contributor.authorCampone, M.
dc.contributor.authorNeven, P.
dc.contributor.authorHuang, C. S.
dc.date.accessioned2024-06-12T11:24:08Z
dc.date.available2024-06-12T11:24:08Z
dc.date.issued2023
dc.departmentTrakya Üniversitesien_US
dc.description.abstract[Abstract Not Available]en_US
dc.identifier.endpageS23en_US
dc.identifier.issn0960-9776
dc.identifier.issn1532-3080
dc.identifier.startpageS22en_US
dc.identifier.urihttps://hdl.handle.net/20.500.14551/26828
dc.identifier.volume68en_US
dc.identifier.wosWOS:001037996400040en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherChurchill Livingstoneen_US
dc.relation.ispartofBreasten_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subject[No Keywords]en_US
dc.titleAbemaciclib plus endocrine therapy (ET) for HR+, HER2-, node-positive, high-risk EBC: results from a pre-planned monarchE overall survival (OS) interim analysis (IA), including 4-year efficacy outcomesen_US
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu